(Getty Images)

Something’s rotten

Eli Lilly's Zepbound rises while Novo Nordisk's Ozempic levels off

Eli Lilly's Zepbound and Mounjaro beat Wall Street expectations while Novo Nordisk's Ozempic and Wegovy disappointed.

8/8/24 10:47AM

Eli Lilly may eventually catch up to Ozempic maker Novo Nordisk when it comes to selling the weight loss drugs that have boomed in popularity in recent years.

Eli Lilly reported on Thursday that sales for Zepbound, which it has only sold for less than a year, reached $1.2 billion, crushing Wall Street estimated. Mounjaro, a similar drug, reached $3.1 billion in sales, making the biggest money-maker on Eli Lilly's portfolio.

As of this quarter three of the four most lucrative drugs Eli Lilly sells are diabetes medications also used for weight loss. (The other is Verzenio, which treats breast cancer.)

Novo Nordisk on Wednesday reported a disappointing quarter for the first time since the boom in obesity medications. Sales for its weight loss drugs — Ozempic and Wegovy — missed expectations and appear to be leveling off.

Demand for weight loss drugs has led both companies to up production to avoid shortages. Eli Lilly and Novo Nordisk have each spent billions to increase production of their obesity drugs.

Earlier this year there were shortages of Ozempic, Novo Nordisk's best-selling drug that kicked off the weight loss drug craze. Those shortages have cleared up but it appears to have limited its growth this year.

Shortages remain for Wegovy, according to a database from the Food and Drug Administration. As of this month none of Eli Lilly's weight loss drugs are facing a shortage.

While Eli Lilly's weight loss drugs had a better quarter than Novo Nordisk's, the latter had a head start in the obesity drug race and is well ahead.

Novo Nordisk's Ozempic made $30 billion this past quarter, compared to $3.1 billion from Eli Lilly's Mounjaro. Ozempic makes up almost half of the market share for that category of weight loss drugs, according to Novo Nordisk.

Nia Warfield

13h

Paramount Skydance reportedly preparing an Ellison-backed Warner Bros. Discovery takeover bid, sending shares soaring

Paramount Skydance is preparing a majority cash bid for Warner Bros. Discovery, The Wall Street Journal reported, sending shares of both companies surging. The Journal’s sources say the deal is backed by the Ellison family, led by David Ellison.

WBD shares were up 30% on the report, while Paramount Skydance jumped 8%.

The offer would cover WBD’s entire business — cable networks, movie studios, the whole enchilada. That comes after WBD announced plans last year to split into two divisions: one for streaming and studios, the other for its traditional cable and TV assets. A recent Wells Fargo note gave WBD a price target hike, primarily because the analysts viewed it as a prime takeover candidate.

If the deal goes through, it would bring together HBO, CNN, DC Studios, and Warner Bros.’ film library with Paramount+, Nickelodeon, and MTV, all under one umbrella.

Exclusive | Paramount Skydance Prepares Ellison-Backed Bid for Warner Bros. Discovery

If the deal goes through, it would bring together HBO, CNN, DC Studios, and Warner Bros.’ film library with Paramount+, Nickelodeon, and MTV, all under one umbrella.

Max Knoblauch

9/10/25

As tariffs take root, August new vehicle prices climb by the most in more than 2 years

According to data from Cox Automotive, 17 vehicle brands raised prices of their new vehicles by more than 3% in August.

Ford Issues Recalls On Some Of Its Mach-E Mustangs And Aviators

Nia Warfield

9/10/25

Netflix taps Amazon to sell streaming ads in new partnership

Starting this fall, brands will be able to access Netflix’s premium ad slots using Amazon’s buying tech.

Millie Giles

WITHDRAWALS

9/10/25

Bank branches are still closing at breakneck speed in the US

Institutions like Chase and Wells Fargo closed 76 locations in just six weeks over the summer, per the OCC.

Indianapolis - March 2016: Chase Bank III

Nia Warfield

9/9/25

Fox and News Corp slide as investors digest $3.3 billion Murdoch succession settlement

Fox and News Corp shares dropped on Tuesday after Rupert Murdoch’s heirs agreed to a $3.3 billion settlement to resolve a long-running succession drama.

Under the deal, Prudence, Elisabeth, and James Murdoch will each receive about $1.1 billion, paid for in part by Fox selling 16.9 million Class B voting shares and News Corp selling 14.2 million shares. The stock sales will raise roughly $1.37 billion on behalf of the three heirs.

The new trust for Lachlan Murdoch will now control about 36.2% of Fox’s Class B shares and roughly 33.1% of News Corp’s stock, granting him uncontested voting authority over both companies for the next 25 years. Originally, the Murdoch trust was designed to hand over voting control of Fox and News Corp to Prudence, Elisabeth, Lachlan, and James after his death.

Investors are weighing the trade-off. Clear leadership under Lachlan may resolve conflict internally, but the share dilution, executed at a roughly 4.5% discount, means long-term investors now hold slightly less clout than before.

Both companies’ stocks were trading close to all-time highs prior to the announcement.

Eli Lilly's Zepbound rises while Novo Nordisk's Ozempic levels off

More Business

Paramount Skydance reportedly preparing an Ellison-backed Warner Bros. Discovery takeover bid, sending shares soaring

Exclusive | Paramount Skydance Prepares Ellison-Backed Bid for Warner Bros. Discovery

Fox and News Corp slide as investors digest $3.3 billion Murdoch succession settlement

Latest Stories